VBWG
Data alert

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI). It is reduced by treatment with angiotensin-converting enzyme (ACE) inhibitors to a significantly greater extent than by treatment with angiotensin type 1 receptor antagonists. This effect is not only sustained, but actually increased over a 6-week time course.1

References are listed at the end of the Data Alert.





Data Alert 14.ppt

Download Data%20Alert%2014.ppt (5 slides - 0.7MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


ACEantigencardiovascularinfarctioninhibitioninhibitorMIMyocardialPAIPlasminogen

Related at vwbg.org

RITA 3: Benefit of early invasive strategy in moderate-risk unstable angina patients

Final results of RITA 3 (Randomized Intervention Trial of unstable Angina) confirm that an interventional strategy results in a statistically significant reduction in the combined outcome of death, nonfatal myocardial infarction (MI), or refractory angina.

HOPE: Effect of long-term therapy with ACE inhibition in high-risk women

Cardiovascular (CV) disease is currently the leading cause of death and the main hospital diagnosis in postmenopausal women.

Curriculum Update #3

Clinical Trials Update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

This Curriculum Update highlights important recent trials of tissue ACE inhibition in patients with cardiovascular disease and preserved left ventricular function.
More related